SANYO and BD Biosciences collaborate on life sciences tools

SANYO North America Corp.’s Biomedical Solutions Division and BD Biosciences, a segment of Becton, Dickinson and Co., last month announced a strategic agreement to jointly promote cutting-edge life science research tools designed to advance cell culture and cell therapy research.

WOOD DALE, Ill.—SANYO North America Corp.'s Biomedical SolutionsDivision and BD Biosciences, a segment of Becton, Dickinson and Co., last monthannounced a strategic agreement to jointly promote cutting-edge life scienceresearch tools designed to advance cell culture and cell therapy research.
 
The companies say the partnership will help them expand their presencein the cell therapy, cell culture and overall life sciences markets.
 
"Leveraging our collective strengths, SANYO and BD Biosciences aim tocontinually advance products that help research and development," said ToshiakiInoue, SANYO Biomedical Solutions' division president, in a statementannouncing the deal. "This collaboration will enable us to offer our customersmore value by integrating our existing products and technologies as well asexploring new cell therapy research tools."
 
According to the companies, their goals in partnering are to developlong-term and short-term co-marketing programs, as well as to researchinnovative ways to combine product technologies and offerings to serve bothcurrent and untapped market applications.
 
SANYO will integrate with BD Biosciences' SySTEMatic ExCELLence SMmarketing campaign as part of the collaboration. The two businesses will alsowork together to grow current and future business by combining SANYO CO2incubators with specialized BD Biosciences Discovery Labware products. Theywill also combine SANYO refrigerators and freezers with BD AdvancedBioprocessing cell culture media and supplements for multiple researchapplications.
 
"This collaboration reflects BD Biosciences' commitment to deliveringbest-in-class, highly integrated products and services to help life scientistsreduce risk and ensure superior quality, while producing clinical-grade stemcell applications," stated Bill Rhodes, president of BD Biosciences.


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022